Clinical and Laboratory Features of 16 Chinese VEXAS Syndrome Patients

16 male VEXAS syndrome patients were identified from a retrospective analysis of 4512 consecutive patients with hematologic abnormalities at a Chinese academic hospital between June 2023 and July 2024. The data, authored by Xiang Ren and last updated in April 2026, profiles patient demographics, UBA1 gene mutations, hematological abnormalities, and multiorgan involvement.

Use Cases

• Characterizing the clinical presentation of VEXAS syndrome based on features like anemia, lymphopenia, and constitutional symptoms.
• Analyzing the prevalence and types of UBA1 gene mutations based on the reported canonical and infrequent variants.
• Studying treatment response patterns based on the reported use of corticosteroids, immunosuppressants, androgens, and erythropoiesis-stimulating agents.
• Investigating associations between hematological diagnoses and systemic symptoms based on reported conditions like CCUS, MDS, and multiorgan involvement.

Strengths

• Provides data on 16 patients, a relatively large cohort for this rare syndrome in a Chinese population.
• Includes specific clinical and genetic details, such as median age (61.5 years), mutation prevalence (81.3%), and dominant variant (p.M41V).
• Covers a defined time range (June 2023 to July 2024) from a single academic center, providing temporal and institutional context.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single center in China, which may limit generalizability to other populations.

Provenance

Source

figshare, authored by Xiang Ren.

Collection Method

Retrospective analysis of patient records at a Chinese academic hospital.

Time Range

June 2023 to July 2024.

Freshness

Last updated 2026-04-16 05:19:16; freshness should be verified.

Geography

China (single-center).